# ICON Plc

ICON Plc is an other based in Houston, Ireland.

## Overview

- **Organization type:** other
- **Headquarters:** Houston, Ireland
- **Region:** Europe
- **Address:** Dublin, Ireland
- **Founded:** 1990
- **Assets under management:** Undisclosed
- **Website:** iconplc.com
- **LinkedIn:** https://www.linkedin.com/company/icon-plc-2

## About

ICON Plc is an SEC-registered investment adviser in HOUSTON, TX, registered since 2022. The firm manages approximately $2.6 billion in regulatory assets. It has 22 employees and 15 investment advisers.

## Sectors

- Healthcare Services
- Digital Health

## People

- Steve Cutler — CEO

## Questions

### What did the PRA Health Sciences acquisition mean for ICON's competitive position?

The July 2021 acquisition of PRA Health Sciences for approximately $12 billion in cash and stock transformed ICON from a mid-tier CRO into one of the world's three largest, alongside IQVIA and Labcorp Drug Development. Beyond scale, the deal brought PRA's mobile and connected health platform, which strengthened ICON's decentralized clinical trial capabilities significantly. Post-merger, the combined entity operates under the ICON name and management structure.

### Which regions drive ICON's clinical trial execution volume?

North America represents the largest single region for ICON's clinical-trial activity, followed by Europe — where the firm maintains substantial operational hubs in Ireland, Bulgaria, and the United Kingdom — and Asia-Pacific, where its 2011 BeijingWits acquisition established a Chinese footprint. The post-PRA combination added further scale in North American oncology and central nervous system trial networks.

### What is ICON's exposure to decentralized clinical trials?

ICON has invested materially in decentralized clinical trial infrastructure, particularly through the PRA Health Sciences acquisition which brought a proprietary mobile and connected health platform. The firm can now run hybrid trials that combine traditional site visits with remote patient monitoring, wearable devices, and direct-to-patient drug shipment. This capability became operationally critical during the COVID-19 pandemic and remains a competitive differentiator in the post-pandemic trial landscape.

## Related profiles

- [MVP](https://altss.com/profile/mvp)
- [Align ENT + Allergy](https://altss.com/profile/align-ent-allergy)

---

Last updated: 2026-06-03T20:00:00.000Z

Canonical page: https://altss.com/profile/icon-plc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology